Kairos Pharma, Ltd. (NYSEAM: KAPA)
Health Care · Biotechnology · US
$0.60
-25.79% today · -92.7% 1Y
Kairos Pharma, Ltd. (NYSEAM: KAPA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.04M and employs 4 people.
Over the last twelve months the share price has lost 92.7%, trading between 0.60 and 8.53.
Tweenvest scores Kairos Pharma, Ltd. across four factors: quality 28/100, value 11/100. Its strongest factor is quality.
KAPA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.04M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.95
- Dividend yield
- —
- Beta (5Y)
- 1.45
- 52-week high
- $8.53
- 52-week low
- $0.60
- Avg volume (3M)
- —
- Shares outstanding
- 3.39M
- Employees
- 4
- Next earnings
- —
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.
- ISIN
- US48301N1046
- Founded
- 2013
- Listed since
- Sep 16, 2024
- Exchange
- NYSE American LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Propanc Biopharma, Inc.NasdaqCM: PPCB | $2.17M | $0.34 | -29.59% |
| HBL - Hadasit Bio-Holdings LtdTASE: HDST-M | $2.16M | ₪0.60 | — |
| CASI Pharmaceuticals, Inc.OTCPK: CASI.F | $2.06M | $0.10 | -9.00% |
| Transgene Biotek LimitedBSE: 526139 | $2.04M | Rs2.55 | +3.24% |
| Oncology Pharma Inc.OTCPK: ONPH | $2.01M | $0.05 | +4.00% |
| Anatara Lifesciences LtdASX: ANR | $1.98M | AU$0.01 | -10.00% |
| Oragenics, Inc.NYSEAM: OGEN | $1.96M | $0.43 | -4.63% |
| BioRestorative Therapies, Inc.NasdaqCM: BRTX | $1.96M | $1.54 | -19.37% |
Figures last refreshed Oct 18, 2026.